2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Ovarian Neoplasms
5
Mesothelioma, Malignant
4
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Mesothelioma
2
Melanoma
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Phase IB
1
Non Hematologic Cancers
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesonephric Gynecologic Cancer
1
Lymphoma
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
157
Gemcitabine
140
Capecitabine
123
Paclitaxel
121
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Docetaxel
98
Leucovorin
97
Cisplatin
90
Radiosurgery
88
Irinotecan
88
Carboplatin
86
Cyclophosphamide
72
Cetuximab
72
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
defactinib
×
Clear all
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled